IP Library Granted Patent US 8,124,794
Granted Patent B2
US 8,124,794 · App. 12/620,412 · Granted Feb 28, 2012

Method for the asymmetric synthesis of beta-lactone compounds

Assignee: Sanford-Burnham Medical Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,794
App. No.
12/620,412
Granted
Feb 28, 2012
Kind
B2
Abstract

The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Claims (66)

1. A compound of the Formula VI:

wherein R 1 is cyclopentyl, cyclohexyl, benzyl, CO 2 Me or MeO—(CH 2 ) 9 —;

R 2 , R 3 and R 4 comprises a hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, a sulfo-oxo group, or a combination thereof;

wherein R 2 is not phenyl or methyl when R 1 is benzyl or —CO 2 Me; and

wherein the stereochemistry at carbons a and b is R or S.

2. A compound of the Formula VI:

wherein R 1 and R 4 are n-butyl and R 2 and R 3 are hydrogen; and

wherein the stereochemistry at carbons a and b is R or S.

3. A compound wherein the compound is a compound selected from the group consisting of (3R,4S)-3-butyl-4-pentyloxetan-2-one, (3R,4R)-3-butyl-4-pentyloxetan-2-one; (3R,4S)-3-butyl-3-methyl-4-pentyloxetan-2-one, (3S,4S)-3-benzyl-3-butyl-4-pentyloxetan-2-one; and (3S,4S)-benzyl 3-butyl-2-oxo-4-pentyloxetane-3-carboxylate.

4. A compound of the Formula VI:

wherein R 1 is cyclopentyl, cyclohexyl, benzyl, CO 2 Me or MeO—(CH 2 ) 9 —;

R 2 , R 3 and R 4 comprises a hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, a sulfo-oxo group, or a combination thereof;

wherein R 2 is not phenyl or methyl when R 1 is benzyl or —CO 2 Me;

wherein the stereochemistry at carbons a and b is R or S; and

wherein said compound is synthesized using a method comprising the steps of:

(a) forming a ketene dimer from an acid chloride; and

(b) hydrogenating the ketene dimer to generate a cis-beta-lactone.

5. A compound of the Formula VI:

wherein R 1 is cyclopentyl, cyclohexyl, benzyl, CO 2 Me or MeO—(CH 2 ) 9 —;

R 2 , R 3 and R 4 comprises a hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, a sulfo-oxo group, or a combination thereof;

wherein R 2 is not phenyl or methyl when R 1 is benzyl or —CO 2 Me;

wherein the stereochemistry at carbons a and b is R or S; and

wherein said compound is synthesized using a method of comprising the steps of:

(a) forming a ketene dimer from an acid chloride;

(b) hydrogenating the ketene dimer to generate a cis-beta-lactone; and

(c) performing an epimerization step further comprising the steps of:

(i) deprotonating the cis-beta lactone; and

(ii) quenching the deprotonated species under low temperature.

6. A compound of the Formula VI:

wherein R 1 is cyclopentyl, cyclohexyl, benzyl, CO 2 Me or MeO—(CH 2 ) 9 —;

R 2 , R 3 and R 4 comprises a hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, a sulfo-oxo group, or a combination thereof;

wherein R 2 is not phenyl or methyl when R 1 is benzyl or —CO 2 Me;

wherein the stereochemistry at carbons a and b is R or S; and

wherein said compound is synthesized using a method comprising the steps of:

(a) forming a ketene dimer from an acid chloride;

(b) hydrogenating the ketene dimer to generate a cis-beta-lactone; and

(c) converting the cis-beta-lactone to a trisubstituted species.

7. The compound of claim 4 , wherein the method is a one-pot synthesis method.

8. The compound of claim 4 , wherein the ketene dimer formed in step (a) is isolated before the hydrogenation step.

9. The compound of claim 8 , wherein the isolation of the ketene dimer is performed by silica gel purification.

10. The compound of claim 4 , wherein the acid chloride has the formula VII below

wherein R is cyclopentyl, cyclohexyl, benzyl, CO 2 Me or MeO—(CH 2 ) 9 —.

11. The compound of claim 4 wherein the step of forming a ketene dimer from an acid chloride comprises using a catalyst wherein said catalyst is selected from the group consisting of QND, O-TBS QND, O-TMS QND, and O-TMS QUIN.

12. The compound of claim 11 wherein the catalyst is QND.

13. The compound of claim 11 wherein the catalyst is O-TMS QUIN.

14. The compound of claim 4 wherein the step of hydrogenating the ketene dimer comprises using a palladium on carbon catalyst.

15. The compound of claim 14 wherein the catalyst is at a concentration of about 1 mol % and 5 mol %.

16. The compound of claim 15 wherein the catalyst is at a concentration of about 1 mol %.

17. The compound of claim 14 wherein the catalyst is accompanied by an amine.

18. The compound of claim 17 wherein the amine is triethylamine.

19. The compound of claim 14 wherein the step of hydrogenating a ketene dimer is performed for 30 minutes at 30 psi H 2 .

20. The compound of claim 4 , wherein the method further comprises an epimerization step.

21. The compound of claim 20 wherein the epimerization step comprises the further steps of:

(a) deprotonating the cis-beta lactone; and

(b) quenching the deprotonated species under low temperature.

22. The compound of claim 21 wherein the step of deprotonating is performed using lithium hexamethyldisilazide (LiHMDS) or related bases such as lithium diisopropylamide (LDA), sodium hexamethyldisilazide (NaHMDS), or lithium tetramethylpiperidide (LiTMP).

23. The compound of claim 21 wherein the step of quenching the deprotonated species is performed using acetic acid.

24. The compound of claim 4 further comprising converting the cis-beta-lactone to a trisubstituted species.

25. The compound of claim 24 wherein the converting step comprises alkylation or acylation.

26. The compound of claim 24 wherein the converting step comprises the further steps of:

(a) enolization of the cis-beta-lactone; and

(b) addition of electrophiles.

27. The compound of claim 26 wherein the enolization step is performed using LDA, LiHMDS or NaHMDS.

28. The compound of claim 26 wherein the electrophiles added to the enolated species from the group consisting of electrophiles.

29. The compound of claim 28 wherein the electrophile is a bulky electrophile or a smaller electrophile.

30. The compound of claim 26 wherein the electrophile comprises CH 3 , benzyl or CO 2 Me.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jan 29, 2018
From: TEXAS A&M UNIVERSITY SYSTEM
To: NIH - DEITR
Reel/Frame 045180/0947 →
CONFIRMATORY LICENSE Recorded Dec 14, 2017
From: TEXAS A&M UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044876/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2012
From: SMITH, JEFFREY W.; AXELROD, FUMIKO; KRIDEL, STEVEN J.
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 027885/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2012
From: ROMO, DANIEL; PUROHIT, VIKRAM; MA, GIL
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 027885/0633 →
CHANGE OF NAME Recorded Nov 30, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025414/0229 →
Continuity (2)
Division 11378961 · Mar 16, 2006
Related Publication 20100173982A1 · Jul 8, 2010